Key result
Cardiovascular disease morbidity and mortality in China are persistently increasing, with an estimated 230 million patients affected and 3 million related deaths annually.
This review provides a comprehensive overview of the escalating cardiovascular disease burden in China and the evolving landscape of medical, interventional, and surgical therapies to address it.
Urgent public health measures are needed to address China's rising CVD burden; leaves open optimal integration of evolving therapies.
Despite revolutionary advancement in medicine over the past century, cardiovascular disease (CVD) remains the leading cause of death and disability in the world. Likewise, the morbidity and mortality of CVD in China are increasing persistently, although the government has taken an active part in the prevention and control of CVD. Here we present an overview regarding the current CVD status in China with respect to various disease phenotypes, as well as the anticipated future trend in accordance with the dynamics and distribution of pathogenesis in Chinese actual situations.
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) conducted a review in Cardiovascular diseases. Cardiovascular disease morbidity and mortality in China are persistently increasing, with an estimated 230 million patients affected and 3 million related deaths annually.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: